| Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 Jan 25 | SYRE Spyre Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 21.66 | 370,000 | 8.01 mm | 370,000 |
| 15 Feb 24 | SYRE Spyre Therapeutics | Common Stock | Grant | Acquire A | No | No | 9.82 | 400 | 3.93 k | 746,907 |
| 1 Feb 24 | SYRE Spyre Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 25.86 | 277,750 | 7.18 mm | 277,750 |
| 24 Nov 23 | SYRE Spyre Therapeutics | Common Stock | Conversion | Acquire C | No | No | 0 | 723,440 | 0.00 | 746,507 |
| 24 Nov 23 | SYRE Spyre Therapeutics | Series A Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 18,086 | 0.00 | 0 |
| 22 Nov 23 | SYRE Spyre Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 10.39 | 374,000 | 3.89 mm | 374,000 |
